



15 April 2021

Clinical trial recruitment platform achieves first major milestone

Melbourne, Australia, Thursday 15 April 2021, Opyl Limited (ASX:OPL) ("Opyl") to announced an update to shareholders on the successful completion of a key milestone in the development of the clinical trial recruitment platform. The platform is continuing its development pathway and on track for market launch on 20 May 2021.

As foreshadowed in the Company's half year announcement on 25 February 2021, the clinical trial recruitment platform achieved its first major milestone of data going live on the platform on 31 March 2021.

"Achieving the 31 March functionality deadline was key in confirming the viability of the platform and the matching algorithm," said Michelle Gallaher, CEO. "Clinical trial data is now live on the platform and the core feature of patients being able to search, self-select and match with any clinical trial in the world, and indicate an interest in participating, is working well."

The next milestones in the development pathway includes a series of focus groups and onboarding a number of clients prepared to trial the platform. The first of a series of five customer and patient focus groups commenced on 8 April 2021 and will continue through until the end of May. Feedback from early clients and from focus group discussions is critical in the ongoing refining of the features and experience on the platform as well as confirming and contributing to the global marketing and sales strategy.

The official launch on 20 May 2021 will be at the International Clinical Trials Day. Michelle Gallaher will be a speaker at a number of events that week, most notably at AusMedtech 2021, introducing the technology by presenting on personalisation of clinical trials and how new technologies are influencing clinical trial design and delivery.

Strong investment interest in Opyl

The company's recent placement was oversubscribed and uptake of the share purchase plan is developing well with strong interest.

"It's been really pleasing to see the strong uptake and interest in the company during the capital raise as we near and achieve major milestones with both the development of novel platforms, continued growth of the company and development of our unique health market solutions", said Dr Julian Chick, Opyl Chairman.

The company will be hosting a webinar on 24 May 2021 for shareholders, introducing the platform and demonstrating the key features and functionality. To sign up to the webinar go to: <https://opyl.webinarninja.com/account/creator/webinars?display=past&page=1>

This announcement has been authorised by Opyl's Board of Directors.

- ENDS -



For media enquiries: Laura Blue +61 416 699 925

For investor enquiries: info@opyl.ai" info@opyl.ai
www.opyl.ai

Opyl is a new generation Australian company that provides leading biopharma and health organisations access to emerging AI-assisted technologies and real-world data insights to understand and improve healthcare and clinical trial design, development and delivery.

Opyl works at the intersection of clinical trials, artificial intelligence, and social media.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment and retention solutions
- clinical trial predictive analytics
- deep social media insights

Our vision is to improve health and wellness by optimising data assets and digital activation to advance technologies for life.

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook